Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for ...

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Purpose-driven marketing elevates brand-consumer relationships beyond transactional interactions. By linking brand values ...

An individual sarcomere contains many parallel actin (thin) and myosin (thick) filaments. The interaction of myosin and actin proteins is at the core of our current understanding of sarcomere ...

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

Recently, a research group led by Prof. Miao Wei from the Institute of Hydrobiology (IHB) of the Chinese Academy of Sciences ...

Actin (red) interacts with myosin, shown in globular form (pink) and a filament form (black line). The model shown is that of H. E. Huxley, modified to indicate bending (curved arrow) near the ...

Hypertrophic cardiomyopathy (HCM) is an inherited disorder that may cause disabling and potentially life-threatening symptoms ...

Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following ...